Craig Lindsley

Displaying 1 - 10 of 13

Potential schizophrenia treatment, discovered at Vanderbilt and being developed by Neumora Therapeutics, entering Phase 1 clinical trial

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials—the third WCNDD therapeutic to reach that benchmark.  

Related Categories: 
Aaron Bender Allison Gregro Basic Sciences biomedical research Carrie Jones clinical trial Colleen Niswender Craig Lindsley Darren Engers Discovery Vanderbilt Research Press release Food and Drug Administration Jeffrey Conn Jerri Rook Julie Engers Kayla Temple neuroscience Olivier Boutaud Pharmacology schizophrenia School of Medicine Basic Sciences Thomas Bridges Warren Center for Neuroscience Drug Discovery

Prothena and Warren Center for Neuroscience Drug Discovery collaborate on new Alzheimer’s disease therapeutics

Prothena and Warren Center for Neuroscience Drug Discovery collaborate on new Alzheimer’s disease therapeutics

Related Categories: 
Research Alzheimer's Disease Press release Bruce Melancon Carrie Jones Craig Lindsley down syndrome Drug Discovery Olivier Boutaud Paul Spearing Pharmacology WCNDD Warren Center for Neuroscience Drug Discovery

Vanderbilt inks collaboration with Neumora Therapeutics, Inc to continue development of investigational treatment for neuropsychiatric disorders

Vanderbilt inks collaboration with Neumora Therapeutics, Inc to continue development of investigational treatment for neuropsychiatric disorders

Related Categories: 
Neumora Health and Medicine Research Aaron Bender Allison Gregro Basic Sciences Carrie Jones clinical pharmacology Colleen Niswender Craig Lindsley Darren Engers dopamine Jerri Rook Julie Engers Kayla Temple neuropsychiatric disorders Olivier Boutaud P. Jeffrey Conn precision medicine schizophrenia Tom Bridges WCNDD Warren Center for Neuroscience Drug Discovery

Ono Extends Drug Discovery Collaboration Agreement with Vanderbilt University

Ono Extends Drug Discovery Collaboration Agreement with Vanderbilt University

Related Categories: 
Ono Pharmaceutical Warren Center for Neuroscience Drug Discovery WCNDD CNS Disorders Drug Discovery Craig Lindsley

A potential new approach for the treatment of schizophrenia

A potential new approach for the treatment of schizophrenia

Related Categories: 
Health and Medicine Research Basic Sciences Canadian Institutes for Health Research Doctoral Foreign Study Award cell reports Colleen Niswender Craig Lindsley James Maksymetz Jeff Conn National Institutes of Health Pharmacology schizophrenia the Vanderbilt Murine Neurobehavior Core Vanderbilt Cell Imaging Shared Resource Vanderbilt International Scholars Program Vanderbilt University Institute of Imaging Science WCNDD

Vanderbilt-discovered drug candidate for Parkinson’s disease enters clinical trials

Vanderbilt-discovered drug candidate for Parkinson’s disease enters clinical trials

Related Categories: 
Appello Basic Sciences clinical trial clinical trials Craig Lindsley Craig W. Lindsley WCNDD Deerfield Management Research Jeffrey Conn P. Jeffrey Conn Parkinsons Parkinson’s disease Warren Center for Neuroscience Drug Discovery Appello Pharmaceuticals

Appello Pharmaceuticals Begins Phase 1 Clinical Trial

Appello Pharmaceuticals Begins Phase 1 Clinical Trial

Related Categories: 
Appello Appello Pharmaceuticals Press release AP-472 Warren Center for Neuroscience Drug Discovery WCNDD mGlu4 PAM Parkinson's Disease Craig Lindsley

Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics

Vanderbilt-developed obesity treatments will be advanced through collaboration with Soleno Therapeutics

Related Categories: 
Research Press release Alan Bentley Basic Sciences Biochemistry Craig Lindsley Jerod Denton obesity Pharmacology Prader-Willi Syndrome Warren Center for Neuroscience Drug Discovery

Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders

Vanderbilt receives $20 million from The William K. Warren Foundation to further treatments for brain disorders

Related Categories: 
Craig Lindsley DAR Jeffrey Conn larry marnett Susan R. Wente The William K. Warren Foundation Vanderbilt Center for Neuroscience Drug Discovery Warren Center for Neuroscience Drug Discovery

Lindsley receives ASPET award honoring drug discovery research

Craig Lindsley, PhD, a leader of Vanderbilt University School of Medicine’s groundbreaking drug discovery program, is being honored by the American Society for Pharmacology and Experimental Therapeutics (ASPET) for his transformative approaches to identifying potential new drugs.

Related Categories: 
ASPET ASPET Award Center for Neuroscience and Drug Discovery Craig Lindsley Department of Medicine